Investors Contact Payment Careers Research Request Physician Portal
Interpace Biosciences®, Inc.
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
  • Diagnostics
  • Support
  • Lab
  • News & Media
    • Press Releases
    • In The News
    • Presentations
    • Events
  • Investors
  • Contact
  • Payment
  • Careers
  • Research Request
  • Physician Portal

Press Releases

Investors
  • Overview
  • News / Events
    • Overview
    • Press Releases
    • In The News
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Presentations
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Contacts
    • RSS News Feed
  • News / Events

  • Overview
  • Press Releases
  • In The News
  • IR Calendar
  • Email Alerts

Interpace Biosciences Announces First Quarter 2025 Financial and Business Results

May 8, 2025

Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk

Apr 24, 2025

Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results

Jan 31, 2025

PancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan

Jan 27, 2025

Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk

Jan 9, 2025

Interpace Biosciences Announces Record Third Quarter 2024 Financial and Business Results

Nov 4, 2024

Interpace Biosciences Announces Capital Restructuring of Its Preferred Stock as a First Step Toward Seeking an Uplisting of Its Common Stock to Nasdaq

Oct 15, 2024

Interpace Biosciences Announces Record Second Quarter 2024 Financial and Business Results

Aug 1, 2024

Interpace Diagnostics® Announces Undefined Extension of Medicare Coverage for PancraGEN®, a Molecular Diagnostic Test That Assesses Cancer Risk of Pancreatic Cysts

Jul 29, 2024

Interpace Diagnostics Announces New Data Analyzing Imbalance of Short Tandem Repeat Alleles for Pancreatic Cancer Detection Published as an ASCO 2024 Abstract

Jun 4, 2024
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...24
© 2025 Interpace Biosciences®, Inc. All Rights Reserved.
Privacy Policy HIPAA Privacy Disclaimer Sitemap Manage Cookie Preferences
We Own Our Future Logo
  • Linkedin